Published in J Gen Intern Med on October 01, 2000
Evidence of bias and variation in diagnostic accuracy studies. CMAJ (2006) 3.34
Variation of a test's sensitivity and specificity with disease prevalence. CMAJ (2013) 1.27
Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies. Prev Chronic Dis (2007) 1.11
Prostate-specific antigen, digital rectal examination and transrectal ultrasonography: a meta-analysis for this diagnostic triad of prostate cancer in symptomatic korean men. Yonsei Med J (2005) 0.84
Prostate cancer: epidemiology and screening. Rev Urol (2003) 0.83
A Review on the Clinical Utility of PSA in Cancer Prostate. Indian J Surg Oncol (2012) 0.80
Early detection and aggressive treatment of prostate cancer: groping in the dark. J Gen Intern Med (2000) 0.78
Brief report: Free prostate-specific antigen test utilization. Consistency with guidelines. J Gen Intern Med (2005) 0.75
Obesity inversely correlates with prostate-specific antigen levels in a population with normal screening results of prostate cancer in northwestern China. Braz J Med Biol Res (2016) 0.75
Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med (1978) 11.42
A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA (1995) 8.60
Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med (1993) 7.29
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA (1992) 6.40
Use of methodological standards in diagnostic test research. Getting better but still not good. JAMA (1995) 5.94
Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA (1993) 5.77
Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med (1994) 5.72
Spectrum bias in the evaluation of diagnostic tests: lessons from the rapid dipstick test for urinary tract infection. Ann Intern Med (1992) 3.64
Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem (1991) 2.96
Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet (1994) 2.83
Estimating diagnostic accuracy from multiple conflicting reports: a new meta-analytic method. Med Decis Making (1994) 2.65
Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA (1995) 2.63
Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin (1993) 2.43
Screening for prostate cancer. American College of Physicians. Ann Intern Med (1997) 2.36
Screening for prostatic carcinoma with prostate specific antigen. J Urol (1992) 2.03
Comparison of a screening test and a reference test in epidemiologic studies. I. Indices of agreement and their relation to prevalence. Am J Epidemiol (1966) 2.02
Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem (1995) 1.98
Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem (1990) 1.95
Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol (1993) 1.91
Risk factors for prostate cancer. Ann Intern Med (1993) 1.90
The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol (1997) 1.67
Prostate-specific antigen: current status. CA Cancer J Clin (2001) 1.63
Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology (1996) 1.59
Assessing quality of a diagnostic test evaluation. J Gen Intern Med (1989) 1.54
Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays. Clin Chem (1997) 1.50
Integrating stratum-specific likelihood ratios with the analysis of ROC curves. Med Decis Making (1993) 1.40
Prostate cancer detection at low prostate specific antigen. J Urol (2000) 1.34
The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol (1992) 1.29
Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology (1995) 1.25
Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology (1996) 1.12
Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol (1997) 1.12
Repeat prostate needle biopsy: who needs it? J Urol (1995) 1.06
Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology (1997) 1.03
Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology (1996) 1.00
Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures. J Urol (1997) 0.99
Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. Clin Chem (1993) 0.97
The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan. Cancer (1997) 0.95
Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies? J Urol (1997) 0.92
Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology (1997) 0.91
Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate Suppl (1996) 0.90
Clinical usefulness of free and complexed PSA. Scand J Clin Lab Invest Suppl (1995) 0.89
Reference test errors bias the evaluation of diagnostic tests for ischemic heart disease. J Gen Intern Med (1988) 0.88
Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. Urology (1995) 0.87
The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer (1997) 0.86
Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem (1996) 0.86
A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol (1996) 0.85
Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng./ml. J Urol (1993) 0.84
Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review. Prostate Suppl (1996) 0.83
Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology (1996) 0.83
Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen. Cancer (1996) 0.83
Percent free prostate-specific antigen: entering a new era in the detection of prostate cancer. Mayo Clin Proc (1997) 0.82
Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. Urol Clin North Am (1997) 0.82
The proportion of free to total prostate specific antigen: a method of detecting prostate carcinoma. Cancer (1996) 0.81
Free and total prostate-specific antigen in a screened population. Br J Urol (1997) 0.81
Variation of free and total prostate-specific antigen levels: the effect on the percent free/total prostate-specific antigen. Arch Pathol Lab Med (1997) 0.81
Significance of serum free prostate specific antigen in the screening of prostate cancer. J Urol (1996) 0.81
The role of free prostate-specific antigen in the diagnosis of prostate cancer. Br J Urol (1997) 0.81
Free-to-total prostate-specific antigen serum concentrations in patients with prostate cancer and benign prostatic hyperplasia. Br J Urol (1996) 0.80
Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. J Urol (1996) 0.80
Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma. Urology (1996) 0.80
The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men. Urology (1995) 0.79
Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. Urology (1996) 0.79
Multicenter comparison of the diagnostic performance of free prostate-specific antigen. Urology (1996) 0.79
Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer? Anticancer Res (1997) 0.78
Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening. Urology (1996) 0.78
Comparability of the Tandem-R and IMx assays for the measurement of serum prostate-specific antigen. Urology (1994) 0.78
Progress in standardization of immunoassays for prostate-specific antigen. Urol Clin North Am (1997) 0.78
Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland. Br J Cancer (1996) 0.77
Clinical evaluation of gamma-seminoprotein in prostate cancer. Prostate (1986) 0.76
Preliminary results of clinical evaluation of the free/total prostate-specific antigen ratio in a multicentric study. Tumori (1997) 0.76
Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer. Eur J Cancer (1996) 0.76
Measurement of prostate specific antigen and gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer. J Urol (1993) 0.76
Does free to total ratio of prostate-specific antigen alter decision-making on prostatic biopsy? Urology (1996) 0.76
Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology. Urology (1996) 0.76
Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia. Urology (1996) 0.76
Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA. Prostate Suppl (1996) 0.76
Measurement of free PSA in the diagnosis and staging of prostate cancer. Int J Cancer (1997) 0.76
Improvement of prostate cancer screening by determination of the ratio free/total PSA in addition to PSA levels. Prostate (1997) 0.76
Regulation of the enzymatic activity of prostate-specific antigen and its reactions with extracellular protease inhibitors in prostate cancer. Scand J Clin Lab Invest Suppl (1995) 0.76
Issues in the assessment of prostate-specific antigen immunoassays. An update. Urol Clin North Am (1997) 0.76
Preliminary clinical evaluation of free/total PSA ratio by the IMMULITE system. Int J Biol Markers (1996) 0.76
Clinical usefulness of free PSA fraction as an indicator of prostate cancer. Int J Cancer (1995) 0.76
Free to total prostatic specific antigen ratio as a new diagnostic tool in prostatic carcinoma. Anticancer Res (1997) 0.75
Dual monoclonal antibody immunoassay for free prostate-specific antigen. Prostate (1996) 0.75
Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med (1993) 7.29
A computer alert system to prevent injury from adverse drug events: development and evaluation in a community teaching hospital. JAMA (1998) 5.50
Improving physician compliance with preventive medicine guidelines. Med Care (1982) 3.78
Outcomes after displaced fractures of the femoral neck. A meta-analysis of one hundred and six published reports. J Bone Joint Surg Am (1994) 3.26
Should adult tetanus immunization be given as a single vaccination at age 65? A cost-effectiveness analysis. J Gen Intern Med (1993) 3.04
Outcome among surviving very low birthweight infants: a meta-analysis. Arch Dis Child (1991) 2.51
Screening asymptomatic adults for cardiac risk factors: the serum cholesterol level. Ann Intern Med (1989) 2.44
Medical and surgical treatment of parapneumonic effusions : an evidence-based guideline. Chest (2000) 2.36
The New Hampshire Mammography Network: the development and design of a population-based registry. AJR Am J Roentgenol (1996) 2.31
The diagnostic accuracy of rapid dipstick tests to predict urinary tract infection. Am J Clin Pathol (1991) 2.18
A randomized, placebo-controlled trial of antimicrobial treatment for children with clinically diagnosed acute sinusitis. Pediatrics (2001) 2.00
Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis (2000) 1.95
A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis (1997) 1.90
Does cost information availability reduce physician test usage? A randomized clinical trial with unexpected findings. Med Care (1982) 1.80
Enteric carriage of vancomycin-resistant Enterococcus faecium in patients tested for Clostridium difficile. Infect Control Hosp Epidemiol (1999) 1.61
U-titer: a utility assessment tool. Proc Annu Symp Comput Appl Med Care (1991) 1.56
A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team. Arch Fam Med (1993) 1.54
A controlled trial of methylprednisolone in the emergency treatment of acute asthma. N Engl J Med (1986) 1.52
The role of exercise testing in screening for coronary artery disease. Ann Intern Med (1989) 1.50
A meta-analytic method for summarizing diagnostic test performances: receiver-operating-characteristic-summary point estimates. Med Decis Making (1993) 1.46
Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases. Chest (1995) 1.45
Technology assessment and pneumoperitoneum therapy for air leaks and pleural spaces. Ann Thorac Surg (1997) 1.41
Theophylline in acute childhood asthma: a meta-analysis of its efficacy. Pediatr Pulmonol (1996) 1.40
Diagnosing pedal osteomyelitis: testing choices and their consequences. J Gen Intern Med (1994) 1.38
Meta-analysis of randomized controlled trials comparing laparoscopic and open appendectomy. Surg Laparosc Endosc (1999) 1.36
The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion (1993) 1.34
Usefulness of blood culture for hospitalized patients who are receiving antibiotic therapy. Clin Infect Dis (2001) 1.20
A cost-effectiveness analysis of the use of a mechanical barrier system to reduce the risk of mistransfusion. Transfusion (1996) 1.19
Effect of in vitro hemolysis on chemical values for serum. Clin Chem (1978) 1.16
The effect of an educational intervention on the perceived risk of breast cancer. J Gen Intern Med (1996) 1.11
Automated utility assessment of global health. Qual Life Res (1996) 1.07
Clinical prediction rules to optimize cytotoxin testing for Clostridium difficile in hospitalized patients with diarrhea. Am J Med (1996) 1.06
Disposable, sheathed, flexible sigmoidoscopy: a prospective, multicenter, randomized trial. The Disposable Endoscope Study Group. Gastrointest Endosc (1995) 1.05
Choosing antihypertensive therapy. J Gen Intern Med (1995) 1.05
The resting electrocardiogram as a screening test. A clinical analysis. Ann Intern Med (1989) 0.98
Assessing the preferences of patients with psoriasis. A quantitative, utility approach. Arch Dermatol (1995) 0.97
Polyamine activation of staphylococcal nuclease. Biochim Biophys Acta (1975) 0.96
The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. Arch Intern Med (1996) 0.96
Effectiveness of helicopter versus ground ambulance services for interfacility transport. J Trauma (1998) 0.94
The clinical evaluation for detecting metastatic lung cancer. A meta-analysis. Am J Respir Crit Care Med (1995) 0.93
Dyspnea ratings for prescribing exercise intensity in patients with COPD. Chest (1996) 0.92
Management of small abdominal aortic aneurysms. Early surgery vs watchful waiting. JAMA (1992) 0.91
Possible sites of origin of human plasma ribonucleases as evidenced by isolation and partial characterization of ribonucleases from several human tissues. Cancer Res (1978) 0.91
A survey of current problems in meta-analysis. Discussion from the Agency for Health Care Policy and Research inter-PORT Work Group on Literature Review/Meta-Analysis. Med Care (1995) 0.90
1989 ARRS President's Award. The validity and utility of sonography in the diagnosis of appendicitis in the community setting. AJR Am J Roentgenol (1989) 0.90
Possible role for poly(A) as an inhibitor of endonuclease activity in eukaryotic cells. Nature (1975) 0.90
Polyamines, ribonucleases, and the stability of RNA. Mol Cell Biochem (1977) 0.90
Cost-effectiveness of preoperative autologous donation in coronary artery bypass grafting. Ann Thorac Surg (1994) 0.89
Peptides isolated from Enterobacter nuclease as potential polyamine binding sites. Biochim Biophys Acta (1976) 0.87
Purification of human spleen ribonuclease by immunoabsorption. Similarity of the enzyme with human liver ribonuclease. J Biol Chem (1976) 0.86
Apparently changing patterns of inheritance in Alport's hereditary nephritis: genetic heterogeneity versus altered diagnostic criteria. Clin Genet (1980) 0.86
Spiral CT colonography: reader agreement and diagnostic performance with two- and three-dimensional image-display techniques. Radiology (2001) 0.86
Randomized controlled trial of sheaths in diagnostic neuroangiography. Radiology (2001) 0.85
Properties of a human liver ribonuclease. Inhibition by polynucleotides and specificity for phosphodiester bond cleavage to yield purine nucleosides at the 5' termini. J Biol Chem (1976) 0.83
Costs and health consequences of cholesterol screening for asymptomatic older Americans. Arch Intern Med (1991) 0.81
Which MR imaging sequences are necessary in determining the need for radiation therapy for cord compression? A prospective study. AJNR Am J Neuroradiol (2007) 0.80
Autologous bone marrow transplantation versus chemotherapy in relapsed/refractory non-Hodgkin's lymphoma: estimates of long-term survival from the recent literature. Am J Hematol (1995) 0.79
Evaluation of a reduced MR imaging sequencing protocol in adult patients with stroke. Radiology (2001) 0.79
Acute toxicity of nonsteroidal antiinflammatory agents: seizure following a mefenamic acid overdose. Drug Intell Clin Pharm (1983) 0.79
Fine-needle aspiration biopsy of abdominal lesions: diagnostic yield for different needle tip configurations. Radiology (1992) 0.79
Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy. Cancer (1999) 0.78
Tetanus immunization in adults. JAMA (1994) 0.78
Using microcomputers to teach sensitivity analysis to medical students. Med Decis Making (1983) 0.77
The development and validation of an instrument to assess acute sinus disease in children. Qual Life Res (1999) 0.77
Surgeons' decision making in patients with chronic wrist pain: role of bilateral three-compartment wrist arthrography--prospective study. Radiology (1996) 0.77
Utility-based estimates of the relative morbidity of visual impairment and angina. Ophthalmic Epidemiol (2000) 0.76
To hell with economics? Am J Public Health (1981) 0.75
Free PSA for detecting prostate cancer. JAMA (1998) 0.75
The utility of prostate-specific antigen for detecting prostate cancer. JAMA (1995) 0.75
Estimates of risk of posttransfusion hepatitis. Am J Med (1992) 0.75
When numbers get serious. J Gen Intern Med (1994) 0.75
PSA thresholds for prostate cancer detection. JAMA (1997) 0.75
Talking about treatment. Ann Intern Med (2000) 0.75
Understanding medical systems. Ann Intern Med (1998) 0.75
Symposium: The role of decision analysis in medical education and practice. Annu Conf Res Med Educ (1979) 0.75
Development of a community-based office of research consultation. J Med Educ (1983) 0.75
Hepatitis B vaccination. Three decision strategies for the individual. Am J Med (1984) 0.75
Evaluation of co-morbidity indices in patients admitted for chronic obstructive pulmonary disease. Monaldi Arch Chest Dis (2005) 0.75
A new approach to the staining of lipids with Sudan Black B: a study by means of polyacrylamide model films containing liposomes. Acta Histochem Suppl (1980) 0.75
Native-valve endocarditis caused by Staphylococcus epidermidis. A histologically confirmed case. Am J Clin Pathol (1987) 0.75
The use of clinical epidemiology as a basis for teaching clinical analysis. QRB Qual Rev Bull (1985) 0.75
Suboccipital dermatomyotomic stimulation and digital blood flow. J Am Osteopath Assoc (1996) 0.75
A strategy for developing educational objectives in medicine: problem-solving skills. J Med Educ (1974) 0.75
Stool collection for occult blood testing. Ann Intern Med (1988) 0.75
Characterization of the 5'-terminus of murine leukemia virus RNA. Biochim Biophys Acta (1974) 0.75
Micromatrix. Apple II. Health Matrix (1983) 0.75
A model study of the Sudan Black B staining of lipids. Acta Histochem Suppl (1981) 0.75
Determinants of physician ordering of preoperative autologous donations. Vox Sang (1994) 0.75
(Histo)chemical aspects of Sudan Black B in various solvents. Acta Histochem Suppl (1981) 0.75
Established rural health systems. EMT J (1981) 0.75
The treatment of localized prostate cancer: what are we doing, what do we know, and what should we be doing? The Prostate Patient Outcome Research Team. Semin Urol (1993) 0.75
Development of a basic science program in a community hospital. Univ Mich Med Cent J (1967) 0.75
Acute Meckel's diverticulitis: diagnosis by ultrasonography. J Clin Ultrasound (1990) 0.75
Published results of surgery for aortoiliac occlusive disease. Ann Vasc Surg (1997) 0.75
Evaluating individualized medical decision analysis. Am J Med (1988) 0.75